Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.
Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.
复制标题
DOI：
10.1080/08830180802495605
复制
发表时间：
2009
影响因子：
5
通讯作者：
Hurwitz JL
中科院分区：
文献类型：
--
作者：
Sealy R;Slobod KS;Flynn P;Branum K;Surman S;Jones B;Freiden P;Lockey T;Howlett N;Hurwitz JL
The human immune system has evolved to recognize antigenic diversity, a strength that has been harnessed by vaccine developers to combat numerous pathogens (e.g. pneumococcus, influenza virus, rotavirus). In each case, vaccine cocktails were formulated to include antigenic variants of the target. To combat HIV-1 diversity, we assembled a cocktail vaccine comprising dozens of envelopes, delivered as recombinant DNA, vaccinia virus and protein for testing in a clinical trial. One vaccinee has now completed vaccinations with no serious adverse events. Preliminary analyses demonstrate early proof-of-principle that a multi-envelope vaccine can elicit neutralizing antibody responses toward heterologous HIV-1 in humans.
登录
查看更多内容
影响因子：
56.9
作者：
Haynes, BF;Fleming, J;Alam, SM
通讯作者：
Alam, SM
影响因子：
64.8
作者：
Altfeld, M;Allen, TM;Walker, BD
通讯作者：
Walker, BD
影响因子：
5.8
作者：
Barnett, SW;Srivastava, IK;Rappuoli, R
通讯作者：
Rappuoli, R
影响因子：
5.4
作者：
Cho, MW;Kim, YB;Martin, MA
通讯作者：
Martin, MA
影响因子：
1.5
作者：
Chakraborty, B;Valer, L;Quiñones-Mateu, ME
通讯作者：
Quiñones-Mateu, ME